Paper Details

  1. Home
  2. Paper Details

Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).

Author: , ConnollyStuart J, CrijnsHarry J G M, GaudinChristophe, HohnloserStefan H, PageRichard L, Torp-PedersenChristian, van EickelsMartin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dronedarone, a multi-channel-blocking drug, demonstrated both rhythm- and rate-controlling properties in patients with atrial fibrillation (AF) or atrial flutter (AFL). In the ATHENA trial, dronedarone 400 mg twice daily reduced the risk of cardiovascular hospitalization or death compared to placebo. Dronedarone delayed the time to first AF or AFL recurrence (737 days vs 498 days) and reduced the need for electrical cardioversion (15% vs 21%). The likelihood of permanent AF or AFL was lower with dronedarone (7.6% vs 12.8%).
Paper Details　
Original Abstract of the Article :
Dronedarone is a multi-channel-blocking drug for the treatment of patients with atrial fibrillation (AF) or atrial flutter (AFL) with rate- and rhythm-controlling properties. A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg b.i.d. for the Prevention...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.amjcard.2010.11.028

データ提供：米国国立医学図書館（NLM）

Dronedarone: A Multi-Channel Solution for Atrial Fibrillation

Atrial fibrillation (AF), like a desert sandstorm, can disrupt the normal rhythm of the heart. This condition, characterized by irregular and rapid heartbeats, can lead to fatigue, dizziness, and an increased risk of stroke. This study, like a team of cardiologists seeking to tame the storm, investigates the effects of dronedarone, a multi-channel-blocking drug, on both the rhythm and rate of the heart in patients with AF.

The researchers, like skilled caravan leaders, analyzed data from the ATHENA trial, a large clinical study that compared the effects of dronedarone to placebo. They found that dronedarone effectively reduced the risk of cardiovascular hospitalization or death from any cause, demonstrating its potential as a valuable treatment for AF.

A Multifaceted Approach to Atrial Fibrillation

The study's findings, like a well-stocked caravan, highlight the multifaceted benefits of dronedarone in managing AF. The drug's ability to both control the heart rate and restore normal rhythm, like a camel caravan navigating a challenging desert terrain, makes it a promising option for patients struggling with this condition.

Understanding Atrial Fibrillation and Treatment Options

AF is a common heart condition, and finding effective treatment strategies is crucial for maintaining cardiac health. This study, like a guidepost in the desert, provides valuable insights into the potential of dronedarone as a treatment option. However, it's essential to consult with a healthcare professional to determine the most appropriate treatment plan for each individual.

Dr. Camel's Conclusion

The desert of heart conditions, like atrial fibrillation, can be a daunting and unpredictable landscape. This study, like a caravan leader discovering a new and effective route, highlights the promise of dronedarone as a treatment option. While further research is needed to fully understand its potential, the findings offer hope for those struggling with AF and provide a reminder that, like a journey through the desert, persistence and innovation can lead to new discoveries and solutions.

Date :
  1. Date Completed 2011-05-23
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

21296333

DOI: Digital Object Identifier

10.1016/j.amjcard.2010.11.028

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.